IFNL3 and hepatocellular carcinoma: The potential mechanism behind the lower HCC recurrence rate with TDF therapy, as opposed to ETV therapy, may be attributed to higher serum interferon (IFN)-λ3 levels induced by TDF, but not ETV [32].